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Abstract Sevelamer hydrochloride (HCl), a calcium-free
phosphate binder, is increasingly used due to concerns
related to calcium exposure and the development of
vascular calcifications. However, a common side effect of
sevelamer HCl, metabolic acidosis, is particularly
concerning in children, as it can contribute to poor growth.
Sevelamer carbonate is now available and has been shown
to increase serum bicarbonate in adult patients. We
conducted a prospective single-center study of pediatric
dialysis patients comparing serum bicarbonate before and
3 months after a switch from sevelamer HCl to sevelamer
carbonate. Inclusion criteria were a minimum of 3 months of
dialysis therapy and either a serum bicarbonate <20mmol/L or
the need for sodium bicarbonate supplementation. Ten
hemodialysis and 14 peritoneal dialysis patients, aged 16±
3 years, were enrolled. Whereas serum calcium and phospho-
rus remained unchanged, serum bicarbonate increased from 20
(17.2–22.0) to 24.5 (20.75–26) mmol/L (p<0.001) after
3 months of sevelamer carbonate therapy. Sodium bicarbonate
supplementation was stopped in all patients (n=10), reducing
the mean daily sodium intake by an average of 2.3 g per
patient. These results demonstrate that sevelamer carbonate
is an effective phosphate binder that improves acid-base
status in pediatric dialysis patients.
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Introduction
Cardiovascular disease is now recognized as one of the
leading causes of morbidity and mortality not only in adults
but also in children with chronic kidney disease (CKD) [1, 2].
Indeed, several studies have shown a high prevalence of
cardiovascular risk factors, such as vascular calcifications
and left-ventricular hypertrophy across the spectrum of CKD
in children [2–5]. Although this process is multifactorial, the
use of calcium-based phosphate binders has been associated
with the development of vascular calcifications in adult and
pediatric patients receiving dialysis [3, 6]. Sevelamer
hydrochloride (HCl), on the other hand, has been shown to
be a safe and effective phosphate binder, providing the same
control of skeletal lesions associated with secondary hyper-
parathyroidism as calcium-based binder therapy [7–9].
Furthermore, sevelamer HCl has been associated with
decreased progression of vascular calcifications in adult
patients undergoing hemodialysis [6, 10].
However, the use of sevelamer HCl has been associated
with a dose-dependent metabolic acidosis in both pediatric
and adult dialysis patients [9, 11]. This side effect is
concerning in children, as chronic metabolic acidosis is
considered a potential risk factor for poor growth. Sevelamer
carbonate is a similar anion exchange resin in which chloride
is replaced by carbonate. It has been shown to be equally
effective in lowering phosphorus, with a reduced incidence of
metabolic acidosis in adult patients on dialysis [12]. Therefore,
this study was designed to assess the effects of sevelamer
carbonate on acid-base status in pediatric dialysis patients.
Material and methods
The patient population was comprised of children receiving
outpatient peritoneal or hemodialysis at the Ronald Reagan
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University of California-Los Angeles (UCLA) Medical
Center. This study was approved by the UCLA Institutional
Review Board, and all patients/parents gave informed consent
to participate. Patients were enrolled in a prospective 3-month
trial with the following inclusion criteria: a minimum of
3 months on automated peritoneal dialysis or hemodialysis,
sevelamer HCl as primary phosphate binder, a serum
bicarbonate <20 mmol/L, or the need for sodium bicarbonate
supplementation. Upon entry into the study, sevelamer HCl
was replaced by an identical dose of sevelamer carbonate, and
the following biochemical variables were determined every
4 weeks: phosphorus, calcium, intact parathyroid hormone
(iPTH), complete blood cell count, serum glucose, sodium,
potassium, chloride, bicarbonate, magnesium, creatinine, urea,
albumin, and alkaline phosphatase. For patients on sodium
bicarbonate supplementation, blood pressure (BP) and inter-
dialytic weight gain (IDWG) were recorded before and every
month after starting sevelamer carbonate. Results are reported
as systolic and diastolic BP indexes (average BP divided by
the 95th percentile for age, sex, and height). Data is presented as
medians with a 25−75 percentile range. Comparisons between
groups were made using nonparametric tests (Kruskal-
Wallis test and Dunn’s posttest for comparisons of more than
two groups, and Wilcoxon signed rank test for two-group
comparisons). A p value of <0.05 was considered significant.
Results
A total of 24 patients aged 16±3 years were enrolled in the
study. Mean duration of dialysis therapy for the ten patients
receiving hemodialysis and 14 receiving peritoneal dialysis
was 9±13 months. At study entry, the dose of sevelamer HCl
was 11.9±3.8 g/day. Six peritoneal dialysis and four hemo-
dialysis patients were receiving sodium bicarbonate supple-
mentation (average of 2.3±1 g/day). Twelve patients were
treated with active vitamin D sterol therapy. Baseline serum
calcium and phosphorus levels were 9.3 (9.2–9.7) mg/dl and
5.7 (4.8–7.2) mg/dl, respectively, and remained stable during
the follow-up period (Fig. 1a). Intact PTH was 330 (136–
668) pg/ml at the beginning of the study and 510 (258–1051)
pg/ml after 3 months (p=0.076). Initial serum bicarbonate
levels were 20.0 (17.2–22.0) mmol/L (20.5 mmol/L in
peritoneal dialysis vs. 20 mmol/L in hemodialysis patients;
p=ns). Levels increased to 24.5 (20.75–26) mmol/L at the
end of the study (p<0.001) (25 mmol/L in peritoneal dialysis
and 23 mmol/L in hemodialysis patients; p=ns) (Fig. 1b).
All sodium bicarbonate supplementation was discontinued
by 2 months in the ten patients previously on alkali therapy.
Among these ten patients, BP and antihypertensive therapy
remained unchanged. Systolic and diastolic BP indexes at the
beginning of the study were 0.93 (0.85–1) and 0.83 (0.78–
0.99), respectively. BP indexes remained stable throughout
the study and were 0.87 (0.81–1.01) and 0.8 (0.65–0.94),
respectively, after 3 months (p=ns). BP indexes were not
different between peritoneal dialysis and hemodialysis
patients. In addition, there was no difference in mean
IDWG at the beginning of the study and after 3 months
[1.1 (0.2–1.2) kg and 1.1 (0.8–1.4) kg, respectively; p=ns].
Discussion
The results of this study demonstrate that sevelamer
carbonate is an effective phosphate binder in pediatric
dialysis patients. Serum calcium and phosphorus remained
unchanged after the switch from sevelamer HCl to
sevelamer carbonate. The median serum iPTH increased
after the switch, but this trend did not reach statistical
significance. In addition, the change to sevelamer carbonate
normalized serum bicarbonate levels, eliminating the need
for alkali therapy previously required with sevelamer HCl.
Fig. 1 a Serum phosphorus
(Phos) and calcium (Ca)
at study entry and after 1, 2,
and 3 months of treatment with
sevelamer carbonate. There was
no significant difference in
serum phosphorus and calcium
at 1, 2, and 3 months of treat-
ment compared with baseline
(p=ns). b Serum bicarbonate
at study entry and after 1, 2,
and 3 months of treatment with
sevelamer carbonate. There was
a significant increase in serum
bicarbonate levels at 1, 2, and
3 months of treatment compared
with baseline (p<0.001)
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Previous studies in both pediatric and adult patients have
demonstrated that metabolic acidosis is a relatively com-
mon adverse side effect of sevelamer HCl. In particular,
Pieper et al., in a crossover study of 18 pediatric CKD
patients (17 dialysis dependent) showed that sevelamer HCl
was as effective as calcium acetate in lowering phosphorus
levels but was associated with a higher rate of metabolic
acidosis (34.4% vs. 3.3%) [9]. Sevelamer carbonate, on the
other hand, in a study of 79 adult hemodialysis patients,
was equivalent to sevelamer HCl in controlling phosphorus
and increased bicarbonate levels by 1.3±4.1 mEq/L over
2 months [12]. Similar findings were described in adult
patients with CKD not yet on dialysis [13].
The increase and normalization of serum bicarbonate
levels after the switch to sevelamer carbonate is of
particular importance in children with CKD in whom
growth retardation remains a significant problem [14, 15].
It is well recognized that children with chronic metabolic
acidosis and normal renal function have poor growth, and
in vitro studies have shown that metabolic acidosis is
associated with a decrease in bone mineralization [16].
Thus, current Kidney Disease Outcomes Quality Initiative
(K/DOQI) nutritional guidelines for children recommend
maintaining a serum bicarbonate level >22 mmol/L [17].
Furthermore, in adult dialysis patients, metabolic acidosis
has been associated with an increased risk of death and
hospitalizations [5, 11].
The improvement in acid-base status had the additional
advantage of allowing the discontinuation of all sodium
bicarbonate supplementation. This reduction in salt intake, on
average 2.3 g/day, may have a beneficial effect in a population
already fluid sensitive and prone to cardiovascular disease
[18]. In our study, there was no change in the IDWG, BP
medications, or BP during the follow-up period. This study
may have been underpowered to detect such differences, and
larger trials are needed. However, discontinuation of sodium
bicarbonate supplementation led to a decrease in the number
of pills per day, which may have a positive impact in a
population where noncompliance is an ongoing issue.
In conclusion, although sevelamer HCl and sevelamer
carbonate are both effective non-calcium-based phosphate
binders in pediatric dialysis patients, sevelamer carbonate has
the additional advantage of maintaining serum bicarbonate
within the normal range. The preferential use of sevelamer
carbonate in pediatric CKD patients, including patients not yet
on dialysis, could have a positive impact on growth, along
with decreasing salt intake and the burden of medications.
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